MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer This article explores the key points surrounding this topic, offering insights into recent developments and their implications. FRIDAY, April 18, 2025 (HealthDay News) — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced genitourinary (GU) toxicity in patients with prostate cancer, according to a study
With growing interest and ongoing research, this topic continues to shape our understanding and approach. The findings highlighted in this article contribute to the broader conversation and open doors for future studies and practical applications. Click for More Details
